# Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2020 · $551,762

## Abstract

PROJECT SUMMARY
This application, “Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for
evaluation of immune checkpoint inhibitors”, is submitted in response to FOA PAR-17-245 “Research Projects
to Enhance Applicability of Mammalian Models for Translational Research”. The goal of this project is to develop
accurate, innovative, and immunogenic mouse models of hepatocellular carcinoma (HCC) that closely mimic the
main etiologies of human non-viral HCC in their pathogenic, transcriptomic, and genomic profiles. These
etiologies include non-alcoholic (NASH) and alcoholic (ASH) steatohepatitis, and type 2 diabetes (T2D).
Although the current major etiologies that underlie HCC development are hepatitis virus B and C (HBV, HCV)
infections, non-viral HCC is predicted to become the major form of this aggressive cancer in the US and Europe
in the not too distant future. While the incidence of non-viral HCC and its associated mortality continue to grow
at an alarming rate, progress in HCC treatment has been disappointingly slow. Recently, however, inhibitors of
the PD-1:PD-L1 checkpoint were found to be much more effective in HCC treatment than any other targeted or
non-targeted therapeutic used in the past. Nonetheless, with objective response rates around 20%, there is much
room for future improvement. Such improvement depends on better understanding of how immune checkpoint
inhibition leads to HCC regression and the identification of adjuvants that enhance the response to this new class
of drugs. Both objectives are dependent on the availability of immunogenic mouse models of human HCC. We
will bank on our recent success in developing an immunogenic mouse model of NASH-driven HCC that is
responsive to PD-1/PD-L1 blockade to develop new and improved mouse models of non-viral HCC that show
rapid and synchronized tumor development, making them highly useful for translational research. In addition to
NASH-driven HCC, we will develop new immunogenic models of ASH-driven HCC. We will also generate a
series of mouse HCC-derived cell lines that give rise to synchronized orthotopic tumors, whose growth and
response to treatment can be monitored by in vivo imaging. To determine and demonstrate the human relevance
of these models, they will be subjected to extensive genomic and transcriptomic characterization and
immunoprofiling. The results of these analyses will be compared to the genomic and transcriptomic profiles of
human HCC using innovative computational tools. The following Specific Aims will be pursued: 1) Use the MUP-
uPA model of NASH driven HCC to compare the carcinogenic efficacy of different NASH-related diets; 2) Use
the MUP-uPA mouse to develop new models of ASH-induced HCC that do not involve HFD feeding; 3) Compare
mouse and human HCC genomic, transcriptomic, and immune profiles; and 4) Generate cell lines from the
different mouse HCC models that will give rise to synchronized orthotopic tumors that are useful for d...

## Key facts

- **NIH application ID:** 9828554
- **Project number:** 5R01CA234128-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Michael Karin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $551,762
- **Award type:** 5
- **Project period:** 2018-12-01 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9828554

## Citation

> US National Institutes of Health, RePORTER application 9828554, Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors (5R01CA234128-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9828554. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*